Comparison of SEPTal and Apical Pacing Sites in PerManent Right Ventricular Pacing

Overview

The SEPTAL-PM study is aimed to compare the right ventricular apical and right ventricular septal position of the right ventricular lead in patients implanted with a pacemaker for conventional anti-bradycardia pacing indications requiring permanent right ventricular pacing ; the primary endpoint is the evolution of the left ventricular ejection fraction assessed by contrast echocardiography at 18-months follow-up.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: May 2016

Detailed Description

Classically the right ventricular pacing (RV) lead position is the RV apex. Several small studies suggested that the septal position which provided a more physiological conduction pattern would improve left ventricular function and dimensions and the patients' outcome. The SEPTAL-PM study is a parallel randomized prospective simple-blinded and multicenter national study with a follow-up duration of 18 month. A total of 180 patients will be enrolled. It was designed to demonstrate that in patients requiring permanent RV pacing for high degree atrio-ventricular conduction disorders the septal pacing would preserve the LVEF and LV dimensions but also the quality of life and the exercise tolerance. The primary endpoint is the evolution of the LVEF assessed by contrast echocardiography. The secondary endpoints are: the quality of life SF 36 questionnaire, the NYHA class, the 6-minute-walk test, the QRS duration, the LV end-systolic and diastolic volumes, the NT-pro BNP, MMP 2-9 and TIMP-1 dosages, stimulation and detection ventricular thresholds. Other reported parameters are: the probes position and electric parameters, all causes of mortality, cardiovascular mortality, hospitalisations for cardiovascular causes, serious adverse events.

Interventions

  • Device: RV lead
    • The RV lead is implanted at the apex or at the interventricular septum

Arms, Groups and Cohorts

  • Active Comparator: APICAL
    • implantation at the apex
  • Experimental: SEPTAL
    • implantation at the interventricular septum

Clinical Trial Outcome Measures

Primary Measures

  • Left ventricular ejection fraction
    • Time Frame: 18 months

Secondary Measures

  • Quality of life questionnaire SF 36
    • Time Frame: 18 months
  • NYHA class
    • Time Frame: 1, 6, 12, 18 months
  • 6-minute-walk test
    • Time Frame: 1, 18 months
  • LV end-systolic and diastolic volumes
    • Time Frame: 18 months
  • QRS duration,
    • Time Frame: 1, 6, 12, 18 months
  • Evolution of cardiac remodeling markers: MMP2-9 and TIMP-1 and NT-pro BNP dosage
    • Time Frame: 18 months
  • All causes and cardiovascular mortality, hospitalizations for cardiovascular cause
    • Time Frame: 18 months
  • Serious adverse events
    • Time Frame: 18 months
  • Stimulation and detection ventricular thresholds
    • Time Frame: 1, 6, 12, 18 months
  • Probes position and electric parameters
    • Time Frame: 18 months

Participating in This Clinical Trial

Inclusion Criteria

  • Age over 18 years old. – Written informed consent. – Permanent cardiac pacing indication for high degree AV block with ventricular rate less than 50 bpm according to the current guidelines of the European Society of Cardiology . – Patients with sinus rhythm or permanent atrial fibrillation. Noninclusion Criteria:

  • Indication for cardiac resynchronization. – Indication for Intra cardiac defibrillators (ICD). – Indication for AV node ablation for patients with atrial fibrillation. – Patients already implanted with a pacemaker or an ICD. – Myocardial infarction within the previous month. – Surgically treated valvulopathy. – Tricuspid Valve prothesis – Cardiac surgery or coronary revascularization planned or within the 3 last months. – Life expectancy less than 18 months. – Pregnancy. – Disability to give informed consent.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rennes University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Christophe Leclercq, MD, PhD, Principal Investigator, Rennes University Hospital

Citations Reporting on Results

Galand V, Martins RP, Donal E, Behar N, Crocq C, Soulie GG, Degand B, Garcia R, Solnon A, Lande G, Probst V, Marjaneh F, Mansourati J, Dupuis JM, Laviolle B, Leclercq C. Septal versus apical pacing sites in permanent right ventricular pacing: The multicentre prospective SEPTAL-PM study. Arch Cardiovasc Dis. 2022 May;115(5):288-294. doi: 10.1016/j.acvd.2021.12.007. Epub 2022 Feb 19.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.